cas 1454847-96-1|| where to buy (1S)-1-(5-fluoro-2-iodophenyl)ethanol

Nom du produit:(1S)-1-(5-fluoro-2-iodophenyl)ethanol

IUPAC Name:(1S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol

Unité d'emballage	Stock disponible	Prix($)
CM336652-5g	in stock	ȃŗ
CM336652-10g	in stock	ƈǪĲ
CM336652-25g	in stock	ǙĲǪ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1454847-96-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1454847-96-1; Formule moléculaire:C8H8FIO; Point de fusion:-; Code SMILES:C[C@H](O)C1=CC(F)=CC=C1I; Densité:

: Numéro de catalogue:CM336652; Poids moléculaire:266.05; Point d'ébullition:; N° Mdl:; Stockage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Lorlatinib; Pfizer announced longer-term follow-up results of the Phase 3 CROWN study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This study aims to evaluate the efficacy and safety of the third-generation anaplastic lymphoma kinase (ALK) inhibitor LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The analysis showed that compared with the first-generation ALK inhibitors, the risk of disease progression or death in patients treated with lorlatinib continued to decrease by 81%, and the risk of brain metastasis progression was reduced by 94%.